Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018890 citationsJournal Articlebronze Open Access

Authors

John F. Seymour · University of Melbourne

Thomas J. Kipps · University of California, San Diego

Barbara Eichhorst · University Hospital Cologne

Peter Hillmen · St James's University Hospital

James D’Rozario · Australian National University

Sarit Assouline · Jewish General Hospital

Carolyn Owen

Abstract

Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 12, pp. 1107-1120

DOI: 10.1056/nejmoa1713976

Field-Weighted Citation Impact: 67.21